News

People with ankylosing spondylitis (AS) who carry a mutation in the gene that encodes the CARD9 protein may be more likely to respond to treatments that block an inflammatory signaling molecule known as interleukin-17 (IL-17), a preclinical study suggests. Scientists found that the protein CARD9 is involved in…

A form of exercise using a device that mimics horseback riding may be an effective intervention to boost muscle strength, limit disease severity, and improve life quality for people with ankylosing spondylitis (AS), according to a new study. The novel approach tested in the trial uses a device called…

Treatment with Rinvoq (upadacitinib) substantially reduced disease activity for most adults with ankylosing spondylitis (AS) who had failed to respond to other treatments, according to one-year data from a clinical trial. “These 1-year data demonstrated consistent improvement and maintenance of response with [Rinvoq] treatment in treatment-refractory patients…

Long-term use of Cimzia (certolizumab pegol) is associated with a higher clinical response to treatment and lower disease activity in people with axial spondyloarthritis (axSpA). This translated to increased productivity for patients, both at work and in household activities. “This highlights the importance of targeting these thresholds to limit…

People with axial spondyloarthritis (axSpA) respond equally well to two types of medications that ease inflammation — tumor necrosis factor (TNF) inhibitors or interleukin-17 (IL-17) inhibitors — regardless of their imaging findings or C-reactive protein (CRP) levels before treatment, a meta-analysis has found. This suggests that neither magnetic resonance imaging…

The responses to Cosentyx (secukinumab) among people with ankylosing spondylitis (AS) and other inflammatory diseases aren’t significantly impacted by a person’s genetic background, a recent study suggests. The findings challenge an existing hypothesis that the variable responses to the therapy in clinical practice could largely be driven by…

An experimental therapy called LNK01001 can safely lower a measure of inflammation, pain, and stiffness in adults with active ankylosing spondylitis (AS) who were refractory or intolerant to non-steroidal anti-inflammatory drugs. These top-line data from a 12-week Phase 2 clinical trial support moving LNK01001 to a Phase 3 trial,…

Exosomes, which are tiny carriers for cellular cargo, are found to have significantly different contents in ankylosing spondylitis (AS) patients compared with healthy people, which in turn has marked influences on immune cell function, according to a recent study. Researchers specifically identified that the profile of molecules called microRNAs…

Women with non-radiographic axial spondyloarthritis (axSpA) tend to be older and have longer, more active disease than men, a small study in Turkey has found. They also tend to have more inflammation of the enthesis, which is where a tendon or ligament inserts into the bone, and peripheral arthritis, or…

More than a dozen genes related to inflammatory cell death were found to be expressed at atypical levels in ankylosing spondylitis (AS) patients in a new study, suggesting these genes could be used to help diagnose the disease. The analyses also identified three small molecules that may help to…